Oncology, Domestic Firms Dominate New China Approvals As Innovation Gathers Pace

China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years.